- 7396 malaria professionals are enjoying the free benefits of MalariaWorld today

Who's online
There are currently 8 users and 262 guests online.
Online users
- nicoM
- patrick sampao
- Inga
- MUTOMBO MULANGU A...
- nick golding
- Kabogo
- Moon
- Sysadmin
News Flash
Recent blog posts
- Where the real battle is won
- Amazing statements by leading malariologists
- How was malaria of 100 years ago eradicated in Palestine/Israel? And without vaccine?
- Winston Hide's courageous move
- Event: Symposium Malaria, maternal and infant health
- Job: Senior Lecturer / Lecturer in Epidemiology
- Job: Inspiring scientists in infectious tropical diseases
- Can we maintain effectiveness of the tools?
- Advertising on MalariaWorld
- Malaria elimination country briefings published by the UCSF Global Health Group
Active forum topics
- The role of community education and involvement in malaria control
- Introduce yourself to MalariaWorld members
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Need for additional group to supplement WHO in fight against malaria
- Sustainable additions to WHO and PMI strategy
New forum topics
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Grand Challemges Canada round 2. Help fund a malaria related project!
- Open Access 2.0:How to achieve this
- Pouring gasoline on the insecticide resistance fire?
- Need for additional group to supplement WHO in fight against malaria
PvDBPII of Myanmar P. vivax isolates displays a high level of genetic polymorphism and is under selective pressure.
The positive rates for blood stage antigens of P. falciparum were higher in Group I than in Group II, but the positive rates for antigens of other stages (PfLSA-1 and PfLSA-3) showed opposite results.
We performed a molecular epidemiologic survey of mutations associated with drug-resistance genes in Plasmodium falciparum in northeastern Myanmar.
Although pharmacokinetic (ethnic-related) factors including resistance of P. falciparum to mefloquine contribute to some treatment failure following treatment with a three-day combination regimen of artesunate-mefloquine, results suggest that artesunate resistance may be emerging at the Thai-Myanmar border.
To determine the frequency of co-infections with Plasmodium species in southern Myanmar, we investigated the prevalence of P. knowlesi.
The proportion of the VK247 subtype in Myanmar was 43.1% (n=25) among 58 positive cases by serodiagnosis and 25.6% (n=24) among 94 positive cases by genetic diagnosis. In both diagnostic methods, the infection status of malaria patients is highly diverse with respect to malaria species, and multiple clonal infections are prevalent in Myanmar.
Extensive genetic polymorphism with diverse allele types was identified in MSP-1 and MSP-2 in P. falciparum field isolates from Myanmar. A high level of mixed infections was also observed, as was a high degree of multiplicity of infection.
These results have significant implications in understanding the nature of P. vivax population circulating in Myanmar as well as providing useful information for malaria vaccine development based on this antigen.